应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
RMD 瑞思迈
盘前交易 05-02 08:51:50 EDT
215.01
+1.02
+0.48%
盘前
216.46
+1.45
+0.67%
08:00 EDT
最高
217.30
最低
211.36
成交量
130.61万
今开
212.65
昨收
213.99
日振幅
2.78%
总市值
315.87亿
流通市值
312.77亿
总股本
1.47亿
成交额
2.80亿
换手率
0.90%
流通股本
1.45亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
瑞思迈2024财年第一财季实现净利润3.00亿美元,同比增加28.76%
自选股智能写手 · 04-28
瑞思迈2024财年第一财季实现净利润3.00亿美元,同比增加28.76%
BUZZ-美股周报:技术支持
Reuters · 04-27
BUZZ-美股周报:技术支持
嗡嗡声--美国股票走势-雪佛龙、英特尔、Alphabet
Reuters · 04-27
嗡嗡声--美国股票走势-雪佛龙、英特尔、Alphabet
瑞思迈股价上涨10.94% 市值涨32.74亿美元
自选股智能写手 · 04-26
瑞思迈股价上涨10.94% 市值涨32.74亿美元
BUZZ-第三季度业绩超出预期,瑞思迈业绩大幅增长
Reuters · 04-26
BUZZ-第三季度业绩超出预期,瑞思迈业绩大幅增长
BUZZ-瑞思迈在澳大利亚证券交易所上市,季度业绩强劲,股价大涨
Reuters · 04-26
BUZZ-瑞思迈在澳大利亚证券交易所上市,季度业绩强劲,股价大涨
睡眠呼吸暂停器械需求强劲,瑞思迈季度利润超预期
Reuters · 04-26
睡眠呼吸暂停器械需求强劲,瑞思迈季度利润超预期
瑞思迈 预计每股收益1.91美元 - 财报前瞻
Reuters · 04-24
瑞思迈 预计每股收益1.91美元 - 财报前瞻
BUZZ-礼来制药降低睡眠呼吸暂停严重程度后,瑞思迈在澳大利亚证券交易所上市的股票下挫
Reuters · 04-18
BUZZ-礼来制药降低睡眠呼吸暂停严重程度后,瑞思迈在澳大利亚证券交易所上市的股票下挫
BUZZ-礼来减肥药在睡眠呼吸暂停试验中获得成功后,瑞思迈业绩下滑
Reuters · 04-17
BUZZ-礼来减肥药在睡眠呼吸暂停试验中获得成功后,瑞思迈业绩下滑
瑞思迈盘中异动 股价大跌5.01%
自选股智能写手 · 04-17
瑞思迈盘中异动 股价大跌5.01%
BUZZ-礼来减肥药在睡眠呼吸暂停试验中获得成功后,ResMed、Inspire Medical业绩下滑
Reuters · 04-17
BUZZ-礼来减肥药在睡眠呼吸暂停试验中获得成功后,ResMed、Inspire Medical业绩下滑
瑞思迈盘中异动 早盘股价大涨5.00%
自选股智能写手 · 03-08
瑞思迈盘中异动 早盘股价大涨5.00%
BUZZ-麦格理称 CSL 和 Resmed 最受澳大利亚医疗保健公司青睐
Reuters · 03-05
BUZZ-麦格理称 CSL 和 Resmed 最受澳大利亚医疗保健公司青睐
BUZZ-飞利浦新型睡眠呼吸暂停器械在美国的销售在 FDA 达成协议后将被停止,瑞思迈因此上涨
Reuters · 01-29
BUZZ-飞利浦新型睡眠呼吸暂停器械在美国的销售在 FDA 达成协议后将被停止,瑞思迈因此上涨
瑞思迈盘中异动 早盘急速拉升5.01%报195.68美元
自选股智能写手 · 01-27
瑞思迈盘中异动 早盘急速拉升5.01%报195.68美元
瑞思迈盘中异动 股价大涨10.61%报190.00美元
自选股智能写手 · 01-25
瑞思迈盘中异动 股价大涨10.61%报190.00美元
BUZZ-瑞思迈第二季度业绩向好,券商上调 PT 值,公司股价上涨
Reuters · 01-25
BUZZ-瑞思迈第二季度业绩向好,券商上调 PT 值,公司股价上涨
BUZZ-瑞思迈在澳大利亚证券交易所上市,第二季度业绩喜人,股价接近 6 个月高点
Reuters · 01-25
BUZZ-瑞思迈在澳大利亚证券交易所上市,第二季度业绩喜人,股价接近 6 个月高点
BUZZ-瑞思迈第二季度业绩乐观,股价上涨
Reuters · 01-25
BUZZ-瑞思迈第二季度业绩乐观,股价上涨
暂无数据
公司概况
公司名称:
瑞思迈
所属市场:
NYSE
上市日期:
--
主营业务:
ResMed Inc.是一家特拉华州公司,成立于1994年3月。该公司在医疗设备和基于云的软件应用程序的开发、制造、分销和营销方面处于全球领先地位,这些应用程序诊断、治疗和管理呼吸系统疾病,包括睡眠呼吸障碍、慢性阻塞性肺病、神经肌肉疾病和其他慢性疾病。该公司的产品和解决方案旨在改善患者的生活质量,减少慢性病的影响,并降低医疗保健成本,因为全球医疗保健系统继续推动从医院到家庭和低成本环境的护理转移。该公司基于云的数字软件健康应用程序以及设备旨在提供联网护理,以改善患者的治疗效果并提高客户的效率。
发行价格:
--
{"stockData":{"symbol":"RMD","market":"US","secType":"STK","nameCN":"瑞思迈","latestPrice":215.01,"timestamp":1714593600000,"preClose":213.99,"halted":0,"volume":1306053,"hourTrading":{"tag":"盘前","latestPrice":216.46,"preClose":215.01,"latestTime":"08:00 EDT","volume":8,"amount":1731.68,"timestamp":1714651200407},"delay":0,"floatShares":145469529,"shares":146907207,"eps":6.499912,"marketStatus":"盘前交易","marketStatusCode":1,"change":1.02,"latestTime":"05-02 08:51:50 EDT","open":212.65,"high":217.3,"low":211.36,"amount":280384607.36664003,"amplitude":0.027758,"askPrice":221.61,"askSize":22,"bidPrice":212,"bidSize":38,"shortable":3,"etf":0,"ttmEps":6.499912,"exchange":"NYSE","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714656600000},"adr":0,"adjPreClose":215.01,"adrRate":0,"dividendRate":0.008744,"preHourTrading":{"tag":"盘前","latestPrice":216.46,"preClose":215.01,"latestTime":"08:00 EDT","volume":8,"amount":1731.68,"timestamp":1714651200407},"postHourTrading":{"tag":"盘后","latestPrice":215.01,"preClose":215.01,"latestTime":"19:59 EDT","volume":34508,"amount":7419579.13,"timestamp":1714607979216},"volumeRatio":0.6384861092226628},"requestUrl":"/m/hq/s/RMD/tweets","defaultTab":"tweets","newsList":[{"id":"2430742021","title":"瑞思迈2024财年第一财季实现净利润3.00亿美元,同比增加28.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430742021","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430742021?lang=zh_cn&edition=full","pubTime":"2024-04-28 00:26","pubTimestamp":1714235192,"startTime":"0","endTime":"0","summary":"3月31日,瑞思迈公布财报,公告显示公司2024财年第一财季净利润为3.00亿美元,同比增加28.76%;其中营业收入为11.97亿美元,同比增加7.16%,每股基本收益为2.04美元。从资产负债表来看,瑞思迈总负债21.85亿美元,其中短期债务34.09百万美元,资产负债比为3.12,流动比率为3.05。机构评级:截至2024年3月31日,当前有20家机构对瑞思迈目标价做出预测,其中目标均价为213.21美元,其中最低目标价为180.00美元,最高目标价为246.77美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404280026368b5b1802&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404280026368b5b1802&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430673629","title":"BUZZ-美股周报:技术支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2430673629","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430673629?lang=zh_cn&edition=full","pubTime":"2024-04-27 04:46","pubTimestamp":1714164361,"startTime":"0","endTime":"0","summary":"** 所有板块均上涨,科技、消费类和通信服务板块涨幅最大** 科技 上涨5.1%。另一方面,IBM 在宣布收购 HashiCorp 、营收不及预期后下跌,芯片制造商英特尔 周五暴跌,原因是第二季度预测令人失望。 尽管如此,半导体指数 仍大涨10%,创下5月下旬以来的最佳一周。周五,埃克森美孚 在第一季度利润不及预期后下跌 ,雪佛龙 在第一季度利润不及预期后早盘下挫,但最终小幅收涨。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430444781","title":"嗡嗡声--美国股票走势-雪佛龙、英特尔、Alphabet","url":"https://stock-news.laohu8.com/highlight/detail?id=2430444781","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430444781?lang=zh_cn&edition=full","pubTime":"2024-04-27 02:04","pubTimestamp":1714154695,"startTime":"0","endTime":"0","summary":" * 个股异动的 Eikon 搜索字符串:[STXBZ] * The Day Ahead 新闻通讯: * The Morning News Call时事通讯: 4月26日 - 周五华尔街主要股指上扬,原因是 Alphabet 公司强劲的季度业绩推动其市值超过 2 万亿美元,多数大型成长股上涨,而通胀数据与预期持平也平息了加息的不安情绪。美东时间13:37,道琼斯工业平均指数 上涨0.65%,报38,331.51点。标准普尔500指数 上涨1.29%,报5,113.68点;纳斯达克综合指数 上涨2.31%,报15,972.848点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430270114","title":"瑞思迈股价上涨10.94% 市值涨32.74亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430270114","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430270114?lang=zh_cn&edition=full","pubTime":"2024-04-26 21:33","pubTimestamp":1714138386,"startTime":"0","endTime":"0","summary":"北京时间2024年04月26日21时33分,瑞思迈股票出现异动,股价大幅拉升10.94%。截至发稿,该股报203.49美元/股,成交量12.3316万股,换手率0.08%,振幅1.27%。最近的财报数据显示,该股实现营业收入11.63亿美元,净利润2.09亿美元,每股收益1.42美元,毛利6.35亿美元,市盈率33.69倍。瑞思迈股票所在的医疗设备行业中,整体涨幅为0.38%。消息层面,截至21时33分,《Needham:维持ResMed评级,由买入调整至买入评级, 目标价由224.00美元调整至236.00美元。》资讯为影响瑞思迈的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042621330787b3f2d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042621330787b3f2d2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430274190","title":"BUZZ-第三季度业绩超出预期,瑞思迈业绩大幅增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2430274190","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430274190?lang=zh_cn&edition=full","pubTime":"2024-04-26 21:09","pubTimestamp":1714136982,"startTime":"0","endTime":"0","summary":"** 在跟踪 RMD 的 15 家券商中,有 9 家将其评为 \"买入 \"或更高评级,6 家评为 \"持有\";PT 中值为 203.50 美元。** 截至上一交易日收盘,RMD股价年累计上涨约7%,而标普500医疗保健板块 的涨幅为2.6%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430326222","title":"BUZZ-瑞思迈在澳大利亚证券交易所上市,季度业绩强劲,股价大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2430326222","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430326222?lang=zh_cn&edition=full","pubTime":"2024-04-26 08:51","pubTimestamp":1714092664,"startTime":"0","endTime":"0","summary":" 4月26日 - ** 在澳大利亚证券交易所上市的瑞思迈 股价上涨多达9.9%,至31.58澳元,将创下自2020年10月30日以来的最佳表现--如果涨势得以保持的话 ** 该股成为基准指数中涨幅最大的股票之一 ** 由于睡眠呼吸暂停设备需求旺盛,这家医疗设备公司的季度利润超出了华尔街预期 ** 花旗银行称,该公司截至 3 月 31 日的季度调整后每股利润为 2.13 美元,高于市场一致预期的每股 1.94 美元。","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430976268","title":"睡眠呼吸暂停器械需求强劲,瑞思迈季度利润超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2430976268","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430976268?lang=zh_cn&edition=full","pubTime":"2024-04-26 06:12","pubTimestamp":1714083137,"startTime":"0","endTime":"0","summary":" 路透社4月25日 - 瑞思迈 周三公布的季度利润超出 华尔街预期,原因是其睡眠呼吸暂停设备需求强劲,股价在延时交易中上涨了9%。瑞思迈生产呼吸机和可提供持续和双侧气道正压的机器,它们用于睡眠呼吸暂停的无创治疗,睡眠呼吸暂停是一种睡眠时气道多次受阻的疾病。瑞思迈的销售额增长了 7%,达到 12 亿美元,略高于预期的 11.7 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429214416","title":"瑞思迈 预计每股收益1.91美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2429214416","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2429214416?lang=zh_cn&edition=full","pubTime":"2024-04-24 04:12","pubTimestamp":1713903131,"startTime":"0","endTime":"0","summary":"* 根据LSEG的数据,12位分析师的平均预期显示,这家总部位于加利福尼亚州圣迭戈的公司的营收将从去年同期的11.2亿美元增至11.67亿美元,增幅为4.5%。* LSEG 分析师对瑞思迈公司的平均预期为每股收益 1.91 美元。* 华尔街对瑞思迈公司 12 个月目标价的中位数为 206.00 美元,高于其上次收盘价 180.35 美元。4月23日 - 上一季度业绩。除非另有说明,所有数字均以美元计。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428302266","title":"BUZZ-礼来制药降低睡眠呼吸暂停严重程度后,瑞思迈在澳大利亚证券交易所上市的股票下挫","url":"https://stock-news.laohu8.com/highlight/detail?id=2428302266","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2428302266?lang=zh_cn&edition=full","pubTime":"2024-04-18 09:12","pubTimestamp":1713402725,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 4月18日 - ** 在澳大利亚证券交易所上市的瑞思迈 股价下跌多达6.3%,至27.050澳元,将创下自2023年8月7日以来最糟糕的一天--如果跌势得以维持的话。 ** 礼来 周三在 (link),其减肥药物有助于减少与睡眠呼吸暂停有关的不规则呼吸发作--这是一种常见的睡眠相关疾病。 ** RMD 生产用于治疗睡眠呼吸暂停的设备,因此引发了竞争担忧 ** 股价跌至 3 月 4 日以来最低点 ** 在澳大利亚证券交易所上市的股票在基准指数中跌幅最大 ** 截至上次收盘,今年股价已上涨 13.5","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428344172","title":"BUZZ-礼来减肥药在睡眠呼吸暂停试验中获得成功后,瑞思迈业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2428344172","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2428344172?lang=zh_cn&edition=full","pubTime":"2024-04-17 22:38","pubTimestamp":1713364728,"startTime":"0","endTime":"0","summary":" (更新) 4月17日 - ** 在礼来 的减肥药在睡眠呼吸暂停患者身上的试验取得成功后,CPAP机制造商瑞思迈 的股价下跌3.68%,至178.06美元。** RMD和INSP生产用于治疗睡眠呼吸暂停的医疗设备,睡眠呼吸暂停是一种潜在的严重睡眠障碍,患者呼吸不规律** 礼来公司的减肥药 tirzepatide 有助于减少 阻塞性睡眠呼吸暂停患者的不规则呼吸频率** 券商摩根大通表示,它认为这种药物的减重效果不足以取代 CPAP 或 Inspire,而是可以将替瑞帕肽与这些疗法一起用于治疗 OSA。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428467653","title":"瑞思迈盘中异动 股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428467653","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428467653?lang=zh_cn&edition=full","pubTime":"2024-04-17 21:47","pubTimestamp":1713361629,"startTime":"0","endTime":"0","summary":"北京时间2024年04月17日21时47分,瑞思迈股票出现波动,股价大幅下挫5.01%。截至发稿,该股报175.59美元/股,成交量75.2714万股,换手率0.51%,振幅4.17%。瑞思迈股票所在的医疗设备行业中,整体跌幅为0.53%。其相关个股中,Innovative Eyewear, Inc.、Predictive Oncology Inc.、Singular Genomics Systems, Inc.涨幅较大,Innovative Eyewear, Inc.、Atrion、瑞思迈较为活跃,换手率分别为2.51%、0.54%、0.51%,振幅较大的相关个股有中进医疗、Innovative Eyewear, Inc.、Repligen Corporation,振幅分别为11.52%、9.49%、5.51%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240417214709792141e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240417214709792141e9&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428314811","title":"BUZZ-礼来减肥药在睡眠呼吸暂停试验中获得成功后,ResMed、Inspire Medical业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2428314811","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2428314811?lang=zh_cn&edition=full","pubTime":"2024-04-17 19:52","pubTimestamp":1713354727,"startTime":"0","endTime":"0","summary":" 4月17日 - ** 礼来 减肥药在睡眠呼吸暂停患者试验中获得成功后,瑞思迈 、Inspire Medical 股价盘前下跌** 瑞思迈股价下跌6.6%至172.60美元,Inspire Medical股价下跌7.7%至204.50美元** 在两项后期试验中,礼来公司的减肥药物帮助阻塞性睡眠呼吸暂停患者减少了 不规则呼吸的频率,平均减少幅度高达 63** LLY 股价上涨 1.2%,至 755.72 美元** 瑞思迈和Inspire Medical生产用于治疗睡眠呼吸暂停的医疗设备,睡眠呼吸暂停是一种潜在的严重睡眠障碍,患者的呼吸会反复停止和开始。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2417794318","title":"瑞思迈盘中异动 早盘股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2417794318","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2417794318?lang=zh_cn&edition=full","pubTime":"2024-03-08 00:28","pubTimestamp":1709828923,"startTime":"0","endTime":"0","summary":"北京时间2024年03月08日00时28分,瑞思迈股票出现波动,股价大幅拉升5.00%。截至发稿,该股报193.49美元/股,成交量46.9456万股,换手率0.32%,振幅2.46%。瑞思迈股票所在的医疗设备行业中,整体涨幅为1.36%。其相关个股中,Nyxoah Sa、Ekso Bionics Holdings, Inc.、Stereotaxis, Inc.涨幅较大,Avinger, Inc.、Sharps Technology Inc.、Bionano Genomics, Inc.较为活跃,换手率分别为101.51%、1.85%、1.33%,振幅较大的相关个股有Avinger, Inc.、Sharps Technology Inc.、Nexgel, Inc,振幅分别为30.54%、15.90%、13.51%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030800284487e76ff8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030800284487e76ff8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2417483410","title":"BUZZ-麦格理称 CSL 和 Resmed 最受澳大利亚医疗保健公司青睐","url":"https://stock-news.laohu8.com/highlight/detail?id=2417483410","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417483410?lang=zh_cn&edition=full","pubTime":"2024-03-05 09:02","pubTimestamp":1709600573,"startTime":"0","endTime":"0","summary":" 3月5日 - ** 麦格理分析师选择澳大利亚生物制药巨头 CSL Ltd 和规模较小的竞争对手 Resmed 作为首选,原因是新产品管道和运营效率的潜在贡献。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2407989648","title":"BUZZ-飞利浦新型睡眠呼吸暂停器械在美国的销售在 FDA 达成协议后将被停止,瑞思迈因此上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2407989648","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2407989648?lang=zh_cn&edition=full","pubTime":"2024-01-29 23:17","pubTimestamp":1706541435,"startTime":"0","endTime":"0","summary":" (更新) 1月29日 - ** 瑞思迈 股价上涨3.72%,至197.22美元** 荷兰健康科技公司飞利浦 表示,它已与美国食品和药物管理局就其睡眠呼吸暂停设备的同意令条款达成 。** 飞利浦将在未来几年内不再在美国销售 治疗睡眠呼吸暂停的新设备,因为该公司正在努力遵守与美国食品及药物管理局达成的协议- Co.** 同意令主要针对飞利浦Respironics公司在美国的业务运营,并将提供一份改进路线图。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2406977837","title":"瑞思迈盘中异动 早盘急速拉升5.01%报195.68美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2406977837","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2406977837?lang=zh_cn&edition=full","pubTime":"2024-01-27 00:00","pubTimestamp":1706284800,"startTime":"0","endTime":"0","summary":"北京时间2024年01月27日00时00分,瑞思迈股票出现波动,股价快速上涨5.01%。截至发稿,该股报195.68美元/股,成交量71.417万股,换手率0.49%,振幅4.62%。最近的财报数据显示,该股实现营业收入11.63亿美元,净利润2.09亿美元,每股收益1.42美元,毛利6.35亿美元,市盈率32.38倍。机构评级方面,在所有23家参与评级的机构中,74%的券商给予买入建议,26%的券商给予持有建议,无券商给予卖出建议。瑞思迈股票所在的医疗设备行业中,整体涨幅为0.33%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202401270000007a3ebeed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202401270000007a3ebeed&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2406214142","title":"瑞思迈盘中异动 股价大涨10.61%报190.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2406214142","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2406214142?lang=zh_cn&edition=full","pubTime":"2024-01-25 22:31","pubTimestamp":1706193090,"startTime":"0","endTime":"0","summary":"北京时间2024年01月25日22时31分,瑞思迈股票出现异动,股价快速上涨10.61%。截至发稿,该股报190.00美元/股,成交量5254股,换手率0.00%,振幅0.26%。瑞思迈股票所在的医疗设备行业中,整体涨幅为0.96%。其相关个股中,瑞思迈、Nyxoah Sa、Nexgel Inc C/Wts 01/12/2026 涨幅较大,Bionano Genomics Inc、Microbot Medical Inc、Nyxoah Sa较为活跃,换手率分别为0.15%、0.06%、0.03%,振幅较大的相关个股有Pulse Biosciences Inc、Nanostring Technologies Inc、Bionano Genomics Inc,振幅分别为3.56%、2.59%、2.42%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024012522313081e38cd7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024012522313081e38cd7&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2406219303","title":"BUZZ-瑞思迈第二季度业绩向好,券商上调 PT 值,公司股价上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2406219303","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2406219303?lang=zh_cn&edition=full","pubTime":"2024-01-25 22:23","pubTimestamp":1706192582,"startTime":"0","endTime":"0","summary":" 1月25日 - ** 呼吸设备制造商瑞思迈 股价盘前上涨9.7%至188.41美元 ** 周三收盘后,该公司公布的 第二季度营收和利润均高于华尔街预期,原因是用于治疗睡眠呼吸暂停的呼吸设备需求强劲。** 券商杰富瑞重申该股 \"持有 \"评级,但将预测价格从 158 美元上调至 164 美元,并预测 RMD 25 财年每股收益为 7.99 美元。** 截至收盘,股价在过去 12 个月中下跌了 24.8","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2406400747","title":"BUZZ-瑞思迈在澳大利亚证券交易所上市,第二季度业绩喜人,股价接近 6 个月高点","url":"https://stock-news.laohu8.com/highlight/detail?id=2406400747","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2406400747?lang=zh_cn&edition=full","pubTime":"2024-01-25 09:05","pubTimestamp":1706144752,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 1月25日 - ** 在澳大利亚证券交易所上市的瑞思迈 股价上涨6.5%至28.500澳元,创下自2023年8月8日以来的最高水平** 如果涨势保持,股价有望创下自5月1日以来的最佳表现 ** 医疗设备制造商 (link) 报告称,第二季度收入增长 12%,达到 12 亿美元。** 该公司称, (link),收入增长得益于对用于治疗睡眠呼吸暂停的呼吸设备的强劲需求** 该公司是基准 S&P/ASX 200 指数 中涨幅最大的公司之一 ** 截至上次收盘,该公司股票今年已上涨 5.2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2406405036","title":"BUZZ-瑞思迈第二季度业绩乐观,股价上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2406405036","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2406405036?lang=zh_cn&edition=full","pubTime":"2024-01-25 07:13","pubTimestamp":1706138038,"startTime":"0","endTime":"0","summary":" 1月24日 - ** 呼吸设备制造商瑞思迈 股价盘后上涨7.7%至185.01美元** 第二季度收入和利润高于华尔街预期,主要得益于治疗睡眠呼吸暂停的呼吸设备需求强劲** RMD 第二季度每股利润为 1.88 美元,高于分析师预计的 1.8 美元,营收为 12 亿美元,高于预计的 11.5 亿美元 - LSEG 数据** 毛利率从 56.5% 下降到 55.1%,主要原因是公司召回含有磁铁的呼吸面罩的相关成本 - RMD** 本月早些时候,美国卫生监管机构将此次召回列为最严重召回。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.resmed.com","stockEarnings":[{"period":"1week","weight":0.1699},{"period":"1month","weight":0.1357},{"period":"3month","weight":0.1102},{"period":"6month","weight":0.407},{"period":"1year","weight":-0.0887},{"period":"ytd","weight":0.2499}],"compareEarnings":[{"period":"1week","weight":-0.01},{"period":"1month","weight":-0.0418},{"period":"3month","weight":0.0228},{"period":"6month","weight":0.1511},{"period":"1year","weight":0.2179},{"period":"ytd","weight":0.0527}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"ResMed Inc.是一家特拉华州公司,成立于1994年3月。该公司在医疗设备和基于云的软件应用程序的开发、制造、分销和营销方面处于全球领先地位,这些应用程序诊断、治疗和管理呼吸系统疾病,包括睡眠呼吸障碍、慢性阻塞性肺病、神经肌肉疾病和其他慢性疾病。该公司的产品和解决方案旨在改善患者的生活质量,减少慢性病的影响,并降低医疗保健成本,因为全球医疗保健系统继续推动从医院到家庭和低成本环境的护理转移。该公司基于云的数字软件健康应用程序以及设备旨在提供联网护理,以改善患者的治疗效果并提高客户的效率。","yearOnYearQuotes":[{"month":1,"riseRate":0.689655,"avgChangeRate":0.023453},{"month":2,"riseRate":0.551724,"avgChangeRate":0.003068},{"month":3,"riseRate":0.62069,"avgChangeRate":0.019281},{"month":4,"riseRate":0.551724,"avgChangeRate":0.015042},{"month":5,"riseRate":0.655172,"avgChangeRate":0.01346},{"month":6,"riseRate":0.703704,"avgChangeRate":0.044828},{"month":7,"riseRate":0.714286,"avgChangeRate":0.023968},{"month":8,"riseRate":0.586207,"avgChangeRate":0.025601},{"month":9,"riseRate":0.413793,"avgChangeRate":0.016915},{"month":10,"riseRate":0.413793,"avgChangeRate":-0.001014},{"month":11,"riseRate":0.758621,"avgChangeRate":0.034553},{"month":12,"riseRate":0.62069,"avgChangeRate":0.02417}],"exchange":"NYSE","name":"瑞思迈","nameEN":"ResMed"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"瑞思迈(RMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供瑞思迈(RMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"瑞思迈,RMD,瑞思迈股票,瑞思迈股票老虎,瑞思迈股票老虎国际,瑞思迈行情,瑞思迈股票行情,瑞思迈股价,瑞思迈股市,瑞思迈股票价格,瑞思迈股票交易,瑞思迈股票购买,瑞思迈股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"瑞思迈(RMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供瑞思迈(RMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}